Recombinant tandem epitope vaccination provides cross protection against Actinobacillus pleuropneumoniae challenge in mice.
Actinobacillus pleuropneumoniae
Antibody
Cross protection
Epitope-based vaccine
Prokaryotic expression
Journal
AMB Express
ISSN: 2191-0855
Titre abrégé: AMB Express
Pays: Germany
ID NLM: 101561785
Informations de publication
Date de publication:
08 Jul 2020
08 Jul 2020
Historique:
received:
30
04
2020
accepted:
15
06
2020
entrez:
10
7
2020
pubmed:
10
7
2020
medline:
10
7
2020
Statut:
epublish
Résumé
Actinobacillus pleuropneumoniae (A. pleuropneumoniae/APP) is the pathogen that causes porcine contagious pleuropneumonia. Actinobacillus pleuropneumoniae is divided into 18 serovars, and the cross protection efficacy of epitopes is debatable, which has resulted in the slow development of a vaccine. Consequently, epitope-based vaccines conferring Actinobacillus pleuropneumoniae cross protection have rarely been reported. In this study, B cell epitopes in the head domain of trimeric autotransporter adhesin were predicted, and 6 epitopes were selected. Then, the predicted epitopes (Ba1, Bb5, C1, PH1 and PH2) were connected by linkers to construct a recombinant tandem antigen (rta) gene. The RTA protein encoded by the recombinant rta gene was expressed, and finally the ICR mice were immunized with the RTA protein with or without inactivated Actinobacillus pleuropneumoniae (serovars 1 and 5b) and challenged with Actinobacillus pleuropneumoniae to evaluate the protective effect of the epitope-based vaccine and combined vaccine. The mice in the RTA-immunized group and RTA plus inactivated Actinobacillus pleuropneumoniae vaccine group had a significant improvement in clinical symptoms and a higher level of antibody in the serum than those in the control group. The RTA immune group had a 40% survival rate after Actinobacillus pleuropneumoniae infection, whereas the combination of RTA and inactivated Actinobacillus pleuropneumoniae produced very strong cross immune protection in mice, at least 50% (RTA IB1 + C5) and at most 100% (RTA IB5 + C1), whereas no cross immunoprotection was found in the solo Actinobacillus pleuropneumoniae immune group. Overall, the combination of the RTA protein and inactivated bacteria significantly enhanced the cross protection effects. This implies that RTA protein in combination with a suitable inactivated Actinobacillus pleuropneumoniae strain could be a candidate vaccine for porcine contagious pleuropneumonia.
Identifiants
pubmed: 32642871
doi: 10.1186/s13568-020-01051-1
pii: 10.1186/s13568-020-01051-1
pmc: PMC7341470
doi:
Types de publication
Journal Article
Langues
eng
Pagination
123Subventions
Organisme : National Natural Science Foundation of China
ID : 31520103917
Références
Sci Rep. 2016 Apr 05;6:24058
pubmed: 27046446
Immunol Lett. 2016 Jul;175:1-7
pubmed: 27133932
Vet Microbiol. 2018 Jul;220:83-89
pubmed: 29885806
Mol Immunol. 2017 Jan;81:108-117
pubmed: 27940254
Vet Microbiol. 2017 Jun;205:14-21
pubmed: 28622855
Vet Microbiol. 2018 Oct;224:17-22
pubmed: 30269785
Vaccine. 2013 Oct 25;31(45):5269-75
pubmed: 24051157
Clin Vaccine Immunol. 2013 Feb;20(2):287-94
pubmed: 23269417
Vaccine. 2005 Mar 18;23(17-18):2322-6
pubmed: 15755620
Vaccine. 2008 Nov 18;26(49):6274-80
pubmed: 18835316
Clin Vaccine Immunol. 2014 Mar;21(3):407-16
pubmed: 24429068
Anim Health Res Rev. 2008 Jun;9(1):25-45
pubmed: 18346296
Microbes Infect. 2002 Feb;4(2):225-35
pubmed: 11880056
Acta Vet Scand. 2010 Sep 11;52:52
pubmed: 20831818
Vet Res. 2010 Sep-Oct;41(5):65
pubmed: 20546697
Vet Microbiol. 2016 Feb 1;183:1-8
pubmed: 26790928
Vet Microbiol. 2009 Jun 12;137(3-4):282-9
pubmed: 19251385
J Basic Microbiol. 2012 Oct;52(5):598-607
pubmed: 22143982
Vet Microbiol. 2015 May 15;177(1-2):175-83
pubmed: 25818350
Infect Immun. 2018 Feb 20;86(3):
pubmed: 29229731
Vet J. 2000 Jan;159(1):18-36
pubmed: 10640409
Infect Immun. 2002 Nov;70(11):6464-7
pubmed: 12379729
J Appl Microbiol. 2018 Jun;124(6):1366-1376
pubmed: 29431246
Vet Microbiol. 2015 May 15;177(1-2):142-53
pubmed: 25818577
Vet Res. 2012 Jan 12;43:2
pubmed: 22240397
Microbiology. 1999 Aug;145 ( Pt 8):2105-2116
pubmed: 10463177